This trial will test how well a combination of two immunotherapy drugs work in treating advanced rare solid tumors.
2 Primary · 1 Secondary · Reporting Duration: 24 months
Experimental Treatment
100 Total Participants · 1 Treatment Group
Primary Treatment: Durvalumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: